Anne-Marie Martin is the Senior Vice President and Global Head of the Experimental Medicine Unit in Oncology Research and Development at GlaxoSmithKline. In this role, Annie leads the translational medicine effort to support asset development across the four Oncology R&D platforms in immuno-oncology (IO), oncology cell therapy (OCT), cancer epigenetics (CE), and synthetic lethality (SL). This includes clinical biomarkers, companion diagnostics, supporting novel biomarker-driven clinical designs, the Oncology Clinical and Translational Consortium, and centralizing human subject sample handling and vendor buying power. Annie plays a vital role in utilizing a personalized medicine approach to expedite the development of innovative therapeutics for treating various oncologic and hematologic indications.
Menu
